Immunovant, Inc.
IMVT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001764013
In the last 90 days, Immunovant, Inc. insiders filed 0 open-market purchases and 9 sales; 226 institutions reported holding it in 13F filings for Q2 2026, worth $4.25B in total; Greenlight Capital is the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 10, 2026, 1:19 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | May 20, 2026 | May 29, 2025 | May 29, 2024 | May 22, 2023 | Jun 8, 2022 |
| Operating expenses | $532.9M | $438.2M | $282.7M | $218.3M | $156.0M |
| Research and development | $456.7M | $360.9M | $212.9M | $160.3M | $101.8M |
| Selling, general and administrative | $76.2M | $77.2M | $57.3M | $48.0M | $54.2M |
| Income tax | $215.0K | $891.0K | $567.0K | $9.00K | -$84.0K |
| Net income | -$505.6M | -$413.8M | -$259.3M | -$211.0M | -$156.7M |
| EPS, basic | $-2.77 | $-2.73 | $-1.88 | $-1.71 | $-1.43 |
| EPS, diluted | $-2.77 | $-2.73 | $-1.88 | $-1.71 | $-1.43 |
| Weighted shares, basic | 182.4M | 151.6M | 138.1M | 123.1M | 109.7M |
| Weighted shares, diluted | 182.4M | 151.6M | 138.1M | 123.1M | 109.7M |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | May 20, 2026 | May 29, 2025 | May 29, 2024 | May 22, 2023 | Jun 8, 2022 |
| Cash and equivalents | $902.1M | $714.0M | $635.4M | $376.5M | $493.8M |
| Accounts receivable | $1.13M | $2.08M | $5.34M | $700.0K | $12.2M |
| Total current assets | $948.8M | $767.7M | $665.8M | $404.3M | $512.9M |
| Property, plant and equipment | $443.0K | $844.0K | $462.0K | $333.0K | $330.0K |
| Total assets | $957.0M | $776.2M | $666.4M | $405.8M | $515.6M |
| Accounts payable | $7.54M | $17.7M | $7.16M | $1.35M | $18.6M |
| Total current liabilities | $104.4M | $68.8M | $48.6M | $43.3M | $44.5M |
| Total liabilities | $104.4M | $68.8M | $48.6M | $43.3M | $45.7M |
| Shareholders' equity | $852.6M | $707.4M | $617.8M | $362.5M | $469.8M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | May 20, 2026 | May 29, 2025 | May 29, 2024 | May 22, 2023 | Jun 8, 2022 |
| Operating cash flow | -$407.3M | -$375.9M | -$214.2M | -$188.2M | -$106.1M |
| Capital expenditures | $8.00K | $759.0K | $360.0K | $197.0K | $254.0K |
| Free cash flow | -$407.3M | -$376.6M | -$214.6M | -$188.4M | -$106.4M |
| Stock-based compensation | $55.7M | $49.5M | $41.1M | $32.3M | $34.2M |
| Investing cash flow | -$8.00K | -$759.0K | -$360.0K | -$197.0K | -$254.0K |
| Financing cash flow | $595.8M | $454.5M | $472.4M | $70.9M | $200.1M |
| Net change in cash | $188.1M | $78.6M | $258.8M | -$117.3M | $93.7M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 3, 2026 | 206.9M | +18.1% | SEC |
| Aug 3, 2026 | 206.6M | +18.5% | SEC |
| May 14, 2026 | 205.3M | +20.1% | SEC |
| Feb 2, 2026 | 203.5M | +19.8% | SEC |
| Nov 3, 2025 | 175.3M | +19.4% | SEC |
| Aug 4, 2025 | 174.3M | +19.1% | SEC |
| May 23, 2025 | 170.9M | +17.0% | SEC |
| Jan 31, 2025 | 169.9M | +16.9% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.